BETA

7 Amendments of Urmas PAET related to 2020/2071(INI)

Amendment 17 #
Draft opinion
Paragraph 2
2. Recognises that the EU depends on a narrow set of countries for a large proportion of its imports of active pharmaceutical ingredients and chemical raw materials; stresses that this over- reliance can poses a risk when limitations in production capacity, excess demand or protectionist measures threaten the proper functioning of global supply chains and potentially undermine the availability of medicines in the EU; calls on the Commission to present a long-term strategy focused on ensuring the EU’s open strategic autonomy in health which includes guidelines on the diversification of pharmaceutical supply chains;
2020/05/18
Committee: INTA
Amendment 21 #
Draft opinion
Paragraph 2
2. Recognises that the EU depends on a narrow set of countries, mainly China and India, for a large proportion of its imports of active pharmaceutical ingredients and chemical raw materials; stresses that this over- reliance can pose a risk when limitations in production capacity, excess demand or protectionist measures threaten the proper functioning of global supply chains and potentially undermine the availability of medicines in the EU; calls on the Commission to present a long-term strategy focused on ensuring the EU’s open strategic autonomy in health;
2020/05/18
Committee: INTA
Amendment 25 #
Draft opinion
Paragraph 3
3. Emphasises that the EU is a leading global exporter of pharmaceutical products; notes that the protection and enforcement of well-balanced IP rights in free trade agreements (FTAs) and at the WTO is crucial toshould serve the development of new medicines and treatments; underlines that the flexibilities provided in the TRIPS agreement can be used to address potential supply shortages in exceptional circumstances; stresses that public health crises should constitute legitimate grounds for activating such flexibilities; and notes that developing countries may need to rely on these flexibilities in order to respond appropriately to the COVID-19 crisis;
2020/05/18
Committee: INTA
Amendment 42 #
Draft opinion
Paragraph 4
4. Emphasises that a broad network of FTAs together with a fully functioning multilateral trading system with the World Trade Organisation and an operational Appellate Body at its core constitute the best way of guaranteeing that multiple sources of manufacturing for essential medicines are available and regulatory standards converge globally;
2020/05/18
Committee: INTA
Amendment 50 #
Draft opinion
Paragraph 5
5. Strongly encourages all countries to join the WTO’s Pharmaceutical Tariff Elimination Agreement; callurges for its scope to be extended to all pharmaceutical and medicinal products; stresses that medical products should at all times be exempted from retaliation in trade disputes;
2020/05/18
Committee: INTA
Amendment 57 #
Draft opinion
Paragraph 6
6. Underlines that a complete repatriation of medical supply chains is not possible in a global economy nor is it desirable; urges the Commission and the Member States to work with the EU’s partners, the WHO and WTO, on establishing an international framework that can prevent the breakdown of supply chains and limit resort to protectionist measures during health crises; calls on the Commission to explore the creation of a common European strategic reserve of medicines, building on the rescEU stockpile initiative.
2020/05/18
Committee: INTA
Amendment 60 #
6. Underlines that a complete repatriation of medical supply chains is not possible in a global economy; urges the Commission and the Member States to work more closely between each other, with the EU’s partners, the WHO and WTO, on establishing an international framework that can prevent the breakdown of supply chains and limit resort to protectionist measures during health crises.
2020/05/18
Committee: INTA